Ingredient name record

Ceramide NP

Korean search label: 세라마이드엔피

Evidence at a glance

2official function labelsIngredient context 2selected human studiesNot a full review

0selected legal receiptsNot a compliance verdict

316product recordsRecorded occurrences

Evidence coverage, not an efficacy or safety score.

Identity & coverage details

Official CosIng inventory context recorded; chemical identity and the complete current regulatory profile remain unverified; selected human studies available.

Recorded presence is not a safety rating, recommended dose or benefit claim.

Identity and formulation context

Names are indexed using case and whitespace normalization. Botanical, chemical and marketing identities have not been independently equated.

Studies tested Ceramide NP-containing lipid mixtures or a specific C15 preparation. Chain length and co-lipids matter; results are not transferred to all ceramides or attributed to Ceramide NP alone.

Discovery spellings and aliases

ceramide · ceramide 3 · ceramide iii · ceramide np · 세라마이드 · 세라마이드 3 · 세라마이드 np · 세라마이드3 · 세라마이드엔피

Search-only metadata; an alias is not proof of chemical equivalence.

Functions listed by CosIng

HAIR CONDITIONINGSKIN CONDITIONING - MISCELLANEOUS

Inventory functions describe the ingredient entry, not a finished product’s effects.

How this inventory match is used

The European Commission’s CosIng inventory is informational. An entry is not permission to use an ingredient or a safety assessment. Listed functions describe the inventory entry; they do not establish a finished product’s effects. The match uses the exact ingredient name, with case and whitespace normalization.

CERAMIDE NP · Inventory identifiers

Inventory record: 92555 · Active
CAS identifiers in this entry: 34354-88-6/100403-19-8 (generic)
EC identifiers in this entry: -/309-560-3

Checked 2026-10-02 · Read the official CosIng entry

Human study context

Primary publications checked 2026-10-03. These are selected studies, not a systematic review, safety rating or instructions for using a product.

A Lipid Mixture Enriched by Ceramide NP with Fatty Acids of Diverse Chain Lengths Contributes to Restore the Skin Barrier Function Impaired by Topical Corticosteroid.

2022 · Original abstract reviewed

Material tested: Cream with a Ceramide NP-enriched lipid mixture of diverse fatty-acid chain lengths versus vehicle.
Study design: Paired forearm-site comparison following topical corticosteroid exposure; allocation details not stated.
Participants: 27 healthy adult men.
Concentration and schedule in the study: Treatment duration, concentration and application frequency absent from the abstract.
What the authors reported: Test sites showed better measured barrier recovery, integrity and hydration than vehicle sites.

What this does not establish

Mixture cannot isolate Ceramide NP; corticosteroid-challenged forearms differ from routine facial use.
Fixed left-test/right-vehicle allocation is described; clinical magnitude absent. Journal publication 2022.

Read the original publication

Monocentric, Vehicle-Controlled, Double-Blind Study to Assess the Short- and Long-Term Effects of a Ceramide NP C15-Containing Emollient on the Skin Microbiome and the Skin Barrier Function in Sensitive Skin.

2026 · Original abstract reviewed

Material tested: Ceramide NP C15-containing emollient versus vehicle; concentration absent from the abstract.
Study design: Exploratory randomized double-blind vehicle-controlled split-body trial.
Participants: 50 participants with sensitive skin.
Concentration and schedule in the study: Six weeks; application frequency absent from the abstract.
What the authors reported: Both formulations improved subjective symptoms. The ceramide formulation reduced measured water loss in the impaired-barrier subgroup; exploratory microbiome shifts were reported.

What this does not establish

A specific chain-length preparation and subgroup finding are not evidence for every Ceramide NP product.
Microbiome changes have unconfirmed clinical meaning; full formulation and quantitative effect sizes absent.

Read the original publication

Still unverified

Selected primary abstracts only, not a systematic review or a complete scientific profile.
Test preparations have not been matched to any Treatfolio product, market, batch or package.
Study schedules are not consumer instructions; regulatory status and personal suitability require separate evidence.
Chemical identity, the complete current regulatory profile and finished-product effects remain unverified.